Physician profile
Neil Thakkar
NPI 1619175833
$6,688.59
in general payments reported to CMS, 2019-2025
31 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $925 · 2021: $898 · 2022: $337 · 2023: $1,389 · 2024: $1,642 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,320.74 | 2020-2025 | Wavewriter Alpha Prime 16, Click, General - Pain Management |
| Nalu Medical, INC. | $1,194.35 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $1,068.26 | 2019-2020 | |
| Biotronik Nro, INC. | $991.40 | 2023-2025 | Prospera, Biotronik |
| Vertos Medical, INC. | $306.49 | 2023-2024 | Mild Device Kit |
| Painteq LLC | $283.05 | 2023-2024 | Painteq |
| Biodelivery Sciences International, INC. | $265.83 | 2019-2021 | |
| Abbott Laboratories | $195.92 | 2020-2023 | Proclaim |
| Nuvasive, INC. | $114.89 | 2023 | Xlif |
| Fidia Pharma USA INC. | $105.68 | 2019-2022 | |
| Pfizer INC. | $91.23 | 2023-2024 | |
| Nevro Corp. | $87.56 | 2019-2024 | Senza |
| Depuy Synthes Sales INC. | $66.28 | 2021-2024 | Orthovisc, Monovisc |
| Scilex Pharmaceuticals INC. | $63.14 | 2019-2021 | |
| Relievant Medsystems, INC. | $58.94 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.44 | 2025 | Relistor |
| Ibsa Pharma INC. | $40.56 | 2024-2025 | Tirosint, Licart, Flector |
| Stryker Corporation | $39.95 | 2019 | |
| Pacira Therapeutics, INC. | $39.59 | 2019 | |
| Medtronic, INC. | $37.42 | 2021-2025 | Inceptiv |
| Spr Therapeutics, INC | $37.22 | 2019 | |
| Bioventus LLC | $32.31 | 2021 | |
| Collegium Pharmaceutical, INC. | $32.11 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $28.44 | 2021 | |
| Alfasigma USA, INC. | $24.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.61 | 2020 | |
| Bausch Health US, LLC | $21.01 | 2019 | |
| Mml US, INC. | $20.08 | 2025 | Reactiv8 |
| Orthogenrx INC. | $15.76 | 2020 | |
| Almatica Pharma LLC | $15.25 | 2020 | |
| Grt US Holding, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Thakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.